MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting

Rhea-AI Summary

MetaVia (Nasdaq: MTVA) announced an accepted poster presentation on Vanoglipel (DA-1241), a GPR119 agonist, at the AASLD Liver Meeting 2025 in Washington, D.C., November 7–11, 2025.

The poster reports results from a 16-week randomized placebo-controlled trial in presumed MASH patients assessing hepatoprotective effects through improvements in inflammation and liver metabolism. Presenting author is Rohit Loomba, M.D., MHSc.

Poster details: Poster 4012, Session: Monday Poster Presenters Hall Hour; Date: Monday, November 10, 2025; Time: 1:00–2:00 pm ET; Location: Convention Center Hall DE, Level 2. A copy will be posted in the Posters section of MetaVia's website after the presentation.

CAMBRIDGE, Mass., Oct. 27, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data on Vanoglipel (DA-1241), a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, has been accepted for a poster presentation at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2025, taking place November 7-11, 2025 in Washington, D.C.

• Title: Vanoglipel (DA-1241), a GPR119 Agonist, Demonstrates Hepatoprotective Effects Through Improving Inflammation and Metabolism in the Liver: A 16-week Randomized Placebo-Controlled Trial in Presumed MASH Patients
• Presenting Author: Rohit Loomba, M.D., MHSc, Professor of Medicine, Chief, Division of Gastroenterology and Hepatology at the University of California at San Diego.
• Poster Number: 4012
• Session: Monday Poster Presenters Hall Hour
• Poster Date: Monday, November 10, 2025
• Poster Time: 1:00-2:00 pm ET
• Poster Location: Convention Center: Hall DE (Posters & Exhibits), Level 2

A copy of the poster will be available on the Posters section of the MetaVia website after the presentation.

About Vanoglipel (DA-1241)
Vanoglipel (DA-1241) is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes (T2D). Agonism of GPR119 in the gut promotes the release of key gut peptides GLP-1, GIP, and PYY. These peptides play a further role in glucose metabolism, lipid metabolism and weight loss. DA-1241 has beneficial effects on glucose, lipid profile and liver inflammation, supported by potential efficacy demonstrated during in vivo preclinical studies. The therapeutic potential of DA-1241 has been demonstrated in multiple pre-clinical animal models of MASH and T2D where DA-1241 reduced hepatic steatosis, inflammation, fibrosis, and improved glucose control. Furthermore, in Phase 1a, 1b and 2a trials, DA-1241 was well tolerated in both healthy volunteers and those with T2DM. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects.

About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing Vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects.

For more information, please visit www.metaviatx.com.

Contacts:

MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com

Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-announces-poster-presentation-on-vanoglipel-da-1241-at-the-aasld-liver-meeting-302594188.html

SOURCE MetaVia Inc.

FAQ

When will MetaVia (MTVA) present the Vanoglipel (DA-1241) poster at AASLD 2025?

MetaVia will present on November 10, 2025, from 1:00–2:00 pm ET.

What does the Vanoglipel (DA-1241) poster (MTVA) cover at AASLD 2025?

It reports a 16-week randomized placebo-controlled trial in presumed MASH patients showing hepatoprotective effects on inflammation and liver metabolism.

Who is the presenting author for MetaVia's (MTVA) poster on Vanoglipel?

The presenting author is Rohit Loomba, M.D., MHSc, Professor of Medicine and Chief of Gastroenterology and Hepatology at UC San Diego.

Where can investors access MetaVia's (MTVA) Vanoglipel poster after AASLD 2025?

A copy will be available in the Posters section of MetaVia's website after the presentation.

What is the poster number and location for MetaVia's (MTVA) Vanoglipel presentation at AASLD?

Poster 4012 will be in Hall DE (Posters & Exhibits), Level 2 at the convention center.